Werewolf Therapeutics(US:HOWL)2024-08-08 11:07Financial Performance - As of June 30, 2024, cash and cash equivalents were $135.3 million, down from $139.2 million as of March 31, 2024, with sufficient funds projected to cover operational expenses through at least Q1 2026[6] - Collaboration revenue for Q2 2024 was $1.1 million, a significant decrease from $8.1 million in the same period of 2023, as the company completed its performance obligations under the collaboration agreement with Jazz Pharmaceuticals[6] - The net loss for Q2 2024 was $17.2 million, compared to a net loss of $5.1 million in Q2 2023[7] - General and administrative expenses were $4.8 million for Q2 2024, slightly up from $4.6 million in Q2 2023[7] - Total operating expenses for Q2 2024 were $20.1 million, compared to $14.1 million in Q2 2023[7] - The weighted-average common shares outstanding for Q2 2024 were 43,521,406, compared to 35,557,701 in Q2 2023[10] Research and Development - Research and development expenses increased to $15.3 million in Q2 2024, compared to $9.6 million in Q2 2023, primarily due to ongoing clinical trials for WTX-124 and WTX-330[7] - WTX-124 achieved three objective clinical responses, including one durable confirmed complete response and two partial responses in patients who were relapsed/refractory to immune checkpoint inhibitor therapy[2] - WTX-330 demonstrated an approximately 23-fold higher systemic drug concentration of IL-12 prodrug compared to previous IL-12 therapeutic strategies at a dose of 0.024 mg/kg[4] - The company anticipates updated data on WTX-124 and WTX-330 in the second half and fourth quarter of 2024, respectively, as part of ongoing clinical trials[1] Contacts - Investor contact is John Norton from Precision AQ, reachable at 212.362.1200[12] - Media contact is Amanda Sellers from Deerfield Group, reachable at 301.332.5574[12] - Company contact is Ellen Lubman, Chief Business Officer of Werewolf Therapeutics[12]